The Orphan Drugs Market is set to Rise as a Result of Pharma Companies
now Looking to Orphan Drugs as an Essential Revenue Stream in 2014
As of January 2014, the EMA lifted the restriction on providing fee reductions to large companies developing new orphan drugs and the Early Access to Medicines Scheme was introduced. Key implementation of this will be a factor into further commercialisation and developments.
Based on this information SMi Group is proud to announce it will be hosting the 3rd conference on Orphan Drugs and Rare Diseases and bringing together leading experts and companies such as Novabiotics, Pfizer, AstraZeneca, GMP Orphan SAS, Genethon and M&C Saatchi and many more to discuss the latest developments in the market.
Benefits of Attending:
For more information please visit http://www.smi-online.co.uk/2014orphandrugs66.asp
If you would like to attend this conference as a delegate please contact John Collins on +44 (0) 207 827 6734 or email@example.com
If you are interested in sponsoring this event contact Alia Malick on +44(0)20 7827 6168 or email firstname.lastname@example.org
If you would like to become a media partner contact Sarah Watson on +44 (0)20 7827 6134 or email email@example.com